Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 3/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074369 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1GAASMN1; SMN2RXFP1 | |
| SCHEMBL4074628 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1GAASMN1; SMN2RXFP1 | |
| SCHEMBL11635055 | 0.81 | KDM4E (0.72) | KDM4EALDH1A1GAASMN1; SMN2RXFP1 | |
| SCHEMBL27645695 | 0.80 | MKNK1 (0.51) | KDM4EALDH1A1GAAMKNK1MKNK2 | |
| SCHEMBL4429820 | 0.79 | KDM4E (0.93) | KDM4EALDH1A1GAASMN1; SMN2RXFP1 | |
| Hydrochloric Acid SCHEMBL6336712 | 0.78 | MKNK1 (0.50) | KDM4EALDH1A1GAAMKNK1MKNK2 | |
| SCHEMBL3523901 | 0.78 | NPY5R (0.55) | KDM4EALDH1A1GAARXFP1MKNK1 | |
| SCHEMBL11253526 | 0.77 | BRD4 (0.62) | KDM4EGAAHSD17B1HSD17B2 | |
| SCHEMBL11539440 | 0.77 | POLB (0.54) | KDM4EALDH1A1GAASMN1; SMN2RXFP1 | |
| SCHEMBL11250248 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1GAASMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| CN-101531631-B | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP | 2011-09-28 | — | — | CN | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| CN-101531631-A | Substituted pyridinones as modulators of p38 map kinase | PHARMACIA CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-1761268-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-08 | — | — | EP | disclosed |
| CN-100486576-C | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2009-05-13 | — | — | CN | disclosed |
| EP-1768983-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| CN-1646125-A | Substituted pyridones as modulators of P38MAP kinase | PHARMACIA CORP (US) | 2005-07-27 | — | — | CN | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
| US-3948903-A | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins | PARKE, DAVIS & COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | KDM4E 3869/4885ALDH1A1 787/4885GAA 2281/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | KDM4E 3921/4885ALDH1A1 741/4885GAA 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.